glp-1 news september 26 2025 Weight-Loss Drug Demonstration Begins July 2026 2025 dominates for GLP-1 trial

Youre close, but I think the comparison undersells the shift

Compared to DPP4 inhibitor, GLP-1RA use was associated with decreased risks of 30 outcomes, including respiratory failure, pneumonia, anemia, post-thrombotic sequelae, and bacterial infections, and increased risk of 13 outcomes, including sleep disturbances, nausea, vomiting, headaches, hypotension, sleep disturbances, and nephrolithiasis

People with certain medical conditions, including a history of pancreatitis or thyroid cancer, may not be good candidates, and should speak with their doctor to decide what management strategies are right for them

Additionally, they might help with sleep apnea and improve overall well-being